Evidence map›Paper›PMID 27009817›Full record

ArticleZhongguo fei ai za zhi = Chinese journal of lung cancer2016

[Analysis of Pathological Types and Clinical Epidemiology of 6,058 Patients with Lung Cancer].

Renfeng Zhang, Yan Zhang, Fengbiao Wen, Kai Wu, Song Zhao

Abstract read
In one paragraph

Article in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. A Simple Method to Train the AI Diagnosis Model of Pulmonary Nodules.Computational and mathematical methods in medicine · 2020
    Article
  5. Epidemiology of lung cancer in northeast of Iran: A 25-year study of 939 patients.Medical journal of the Islamic Republic of Iran · 2020
    Article
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Article
  13. [Clinical and Prognosic Anylasis of 30 Cases with Double Primary Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2017
    Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Renfeng ZhangDepartment of Thoracic Surgery, the First Affiliated Hospital, Zhengzhou University, Zhengzhou Key Laboratory of 
Thoracic Oncology, Zhengzhou 450052, China.
Yan ZhangDepartment of Thoracic Surgery, the First Affiliated Hospital, Zhengzhou University, Zhengzhou Key Laboratory of 
Thoracic Oncology, Zhengzhou 450052, China.
Fengbiao WenDepartment of Thoracic Surgery, the First Affiliated Hospital, Zhengzhou University, Zhengzhou Key Laboratory of 
Thoracic Oncology, Zhengzhou 450052, China.
Kai WuDepartment of Thoracic Surgery, the First Affiliated Hospital, Zhengzhou University, Zhengzhou Key Laboratory of 
Thoracic Oncology, Zhengzhou 450052, China.
Song ZhaoDepartment of Thoracic Surgery, the First Affiliated Hospital, Zhengzhou University, Zhengzhou Key Laboratory of 
Thoracic Oncology, Zhengzhou 450052, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectiveThe epidemiology of lung cancer changes with time, region, and population. The pathological and clinical characteristics of patients with primary bronchial lung cancer were retrospectively analyzed to understand the epidemic trend of lung cancer in recent years.

methodsWe reviewed the clinical data of patients with primary bronchogenic carcinoma. These patients, who are permanent residents of Henan province, were treated in the First Affiliated Hospital of Zhengzhou University from 2012 to 2014. The distributions of gender, age, urban/rural residency, smoking history, drinking history, operation history, and histological types of tumor were compared among the patients and analyzed.

resultsA total of 6,058 cases of lung cancer were collected, including 1,495 cases in 2012, 2,070 cases in 2013 and 2,493 cases in 2014. The proportions of male to female patients with lung cancer were 2.26:1, 2.29:1 and 2.20:1 in 2012 to 2014, respectively (χ²=0.367, P=0.832). The age of onset was 60-69 years old, which accounted for 35.72% of the patients, and exhibited statistically significant differences between male and female patients (χ²=109.848, P<0.001). Moreover, differences in the pathological types of patients with lung cancer were statistically significant in 2012-2014 (χ²=25.344, P=0.013). Lung adenocarcinoma accounted for 38.5% and 73.63% in male and female patients, respectively, and the difference was statistically significant (χ²=562.382, P<0.001). Adenocarcinoma also accounted for 60.62%, 56.59%, 49.84%, 45.15%, 47.03% and 41.25% in all ages of patients with lung cancer; the difference was statistically significant (χ²=48.886, P<0.001). Furthermore, the proportions of various pathological types in rural and urban patients were statistically significant among the five regions of Henan Province. The proportions of squamous cell carcinoma were the highest in smoking and drinking patients, accounting for 38.39% and 37.37%, respectively. About 15.4% of the patients included in the study received surgical treatment.

conclusionsThe proportion of adenocarcinoma in all types of lung cancer has increased in recent years, whereas the incidence of squamous cell carcinoma has declined. Adenocarcinoma is common in male patients with lung cancer as well as in young- and middle-aged patients. Squamous cell carcinoma is associated with smoking and drinking in male patients.

Indexed as

AdenocarcinomaAdenocarcinoma of LungAdultAgedAged, 80 and overCarcinoma, Squamous CellChinaFemaleHumansLung NeoplasmsMaleMiddle AgedNeoplasm StagingRetrospective StudiesRisk FactorsSmoking

Identifiers

PMID27009817
PMCPMC5999820

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.